【摘要】 目的:观察前列腺素E1对糖尿病肾病患者的疗效及炎症因子抑制作用。方法:2013年6月²015年6月,糖尿病肾病患者86例随机分为观察组和对照组。对照组给予常规限制,辅以常规降血压及血糖治疗手段。观察组在对照组基础上加用前列腺素E₁治疗。治疗后比较两组患者24h尿蛋白量、血肌酐以及血尿素氮等肾功能指标、细胞间黏附因子-1（s ICAM-1）及超敏C反应蛋白（hs-CRP）含量变化。结果:治疗后两组患者的24 h尿蛋白量、血肌酐、血尿素氮、sICAM-1及hs-CRP等指标均较治疗前显著降低（P<0.05）,且观察组患者的各项指标明显优于对照组（P<0.05）。两组患者均未发生严重的药品不良反应。结论:前列腺素E₁对糖尿病肾病患者具有较好的治疗疗效及炎症因子抑制作用,且安全性较高,值得推广使用。更多还原

【Abstract】 Objective:To study the efficacy of prostaglandin E1 in the patients with diabetic nephropathy and its inhibition on inflammatory factors.Methods:Totally 86 cases of diabetic nephropathy from June 2013 to June 2015 in our hospital were selected,and according to the random number,they were randomly divided into the observation group and the control group.The control group was treated with the conventional dietary restriction and therapy regimen including lowering blood pressure and blood sugar.The patients in the observation group were given prostaglandin E1 additionally.After the treatment,24 h urine protein quantity,serum creatinine and blood urea nitrogen and the other basic indicators of renal function and the contents of s ICAM-1 and hs-CRP were detected.Results:After the treatment,the contents of 24 h urine protein,serum creatinine,blood urea nitrogen,s ICAM-1 and hs-CRP in the two groups were notably decreased when compared with those before the treatment,and the decrease in the observation groups was more significant than that in the control group,and the difference was statistically significant(P <0.05).During the course of treatment,no obvious adverse reactions appeared in the two groups.Conclusion:Prostaglandin E1 in the adjuvant treatment of diabetic nephropathy patients shows better therapeutic efficacy and inhibition on inflammatory factors with higher security,which should be promoted in clinics.更多还原